| Literature DB >> 35237872 |
Shirui Lu1, Xin Hu1, Jun Zhang1, Ying Zhu1, Wei Zhou1, Yani Liu2, Youbin Deng1.
Abstract
BACKGROUND: Post-systolic shortening (PSS) is an important indicator for early identifying myocardial dysfunction. We aimed to investigate the predictive value of PSS assessed with speckle tracking automated functional imaging (AFI) on adverse events in patients with stable coronary artery disease (CAD) and preserved systolic function.Entities:
Keywords: Automated functional imaging; Global longitudinal strain; Post-systolic shortening; Speckle tracking echocardiography; Stable coronary artery disease
Year: 2022 PMID: 35237872 PMCID: PMC8891405 DOI: 10.1186/s13244-022-01174-y
Source DB: PubMed Journal: Insights Imaging ISSN: 1869-4101
Fig. 1Representative cases. The bull’s eye map of post-systolic index (PSI) and longitudinal strain curves of six myocardial segments in the apical four-chamber view of the patients without (A, B) and with (C, D) major adverse cardiovascular events during follow-up. Both patients showed normal global longitudinal strain (GLS) and left ventricular ejection fraction (LVEF). A Normal bull’s eye map of PSI with an average value of 3.3%. B Normal strain curves with little or no sign of post-systolic shortening (PSS). C Abnormal bull’s eye map of PSI with an increased average value of 16.0%. D Abnormal strain curves where the green segment exhibits obvious PSS
Baseline characteristics stratified by follow-up outcome
| Overall population ( | With event ( | Without events ( | ||
|---|---|---|---|---|
| Age, year | 59 ± 10 | 64 ± 10 | 58 ± 10 | 0.009* |
| Male | 148 (73) | 21 (70) | 127 (73) | 0.735 |
| Body mass index, kg/m2 | 22.9 ± 2.7 | 22.8 ± 2.9 | 23.0 ± 2.6 | 0.814 |
| Systolic blood pressure, mm Hg | 129 ± 17 | 134 ± 18 | 128 ± 17 | 0.096 |
| Diastolic blood pressure, mm Hg | 78 ± 11 | 79 ± 14 | 77 ± 11 | 0.551 |
| Heart rate, bpm | 70 ± 10 | 70 ± 11 | 71 ± 11 | 0.729 |
| Smoke | 50 (24.5) | 7 (23.3) | 43 (24.7) | 0.871 |
| Hypertension | 119 (58.3) | 22 (73.3) | 97 (55.7) | 0.071 |
| Diabetes | 72 (35.3) | 15 (50.0) | 57 (32.8) | 0.068 |
| ACEI/AT2-antagonists | 81 (39.7) | 16 (53.3) | 65 (37.4) | 0.099 |
| Beta-blockers | 121 (59.3) | 20 (66.7) | 101 (58.0) | 0.375 |
| Calcium blocker | 99 (48.5) | 12 (40.0) | 87 (50.0) | 0.311 |
| Aspirin | 168 (82.4) | 25 (83.3) | 143 (82.2) | 0.879 |
| PCI | 33 (16.2) | 7 (23.3) | 26 (14.9) | 0.269 |
| CABG | 90 (44.1) | 15 (50.0) | 75 (43.1) | 0.482 |
| Carotid plaque | 128 (62.7) | 20 (66.7) | 108 (62.1) | 0.630 |
| ST depression ≥ 0.5 mm | 77 (37.7) | 13 (43.3) | 64 (36.8) | 0.494 |
| T wave inversion ≥ 1 mm | 67 (32.8) | 14 (46.7) | 53 (30.5) | 0.081 |
| Pathological Q wave ≥ 0.04 s | 32 (15.7) | 4 (13.3) | 28 (16.1) | 0.701 |
| LAD | 152 (74.5) | 26 (86.7) | 126 (72.4) | 0.098 |
| LCX | 114 (55.9) | 21 (70.0) | 93 (53.4) | 0.092 |
| RCA | 111 (54.4) | 21 (70.0) | 90 (51.7) | 0.063 |
| NYHA functional class III–IV | 61 (29.9) | 16 (53.3) | 45 (25.9) | 0.002* |
Data are presented as mean ± SD or median (interquartile range) for continuous variables, and count (%) for categorical variables
ACEI: angiotensin-converting enzyme inhibitors; AT: angiotensin; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; LAD: left anterior descending artery; LCX: left circumflex artery; RCA: right coronary artery; NYHA: New York Heart Association; IVS: interventricular septum; LVPW: left ventricular posterior ventricular wall; LVEDD: left ventricular end-diastolic diameter; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; LVMI: left ventricular mass index; LVEF: left ventricular ejection fraction; GLS: global longitudinal strain; PSI: post-systolic index; PSS: post-systolic shortening
P-value marks trend for events group vs. without events group (*p < 0.05)
Baseline characteristics stratified by left ventricle walls with pathological PSS
| Walls with presence of PSS | No walls ( | 1–2 walls ( | ≥ 3 walls ( | |
|---|---|---|---|---|
| Age, year | 58 ± 10 | 59 ± 10 | 62 ± 11 | 0.222 |
| Male | 72 (73) | 44 (71) | 32 (74) | 0.925 |
| Body mass index, kg/m2 | 22.7 ± 2.5 | 23.3 ± 3.0 | 23.1 ± 2.7 | 0.353 |
| Systolic blood pressure, mm Hg | 128 ± 18 | 129 ± 17 | 130 ± 16 | 0.795 |
| Diastolic blood pressure, mm Hg | 78 ± 11 | 77 ± 10 | 78 ± 12 | 0.749 |
| Heart rate, bpm | 71 ± 10 | 70 ± 9 | 70 ± 10 | 0.797 |
| Smoke | 29 (29.3) | 10 (16.1) | 11 (25.6) | 0.165 |
| Hypertension | 55 (55.6) | 35 (56.5) | 29 (67.4) | 0.392 |
| Diabetes | 36 (36.4) | 16 (25.8) | 20 (46.5) | 0.088 |
| Carotid plaque | 60 (60.6) | 38 (61.3) | 30 (69.8) | 0.561 |
| ST depression ≥ 0.5 mm | 38 (39.4) | 21 (32.3) | 18 (41.9) | 0.697 |
| T wave inversion ≥ 1 mm | 40 (40.4) | 20 (32.3) | 18 (41.9) | 0.503 |
| Pathological Q wave ≥ 0.04 s | 15 (15.2) | 8 (12.9) | 9 (20.9) | 0.528 |
| LAD | 70 (71.7) | 47 (75.8) | 35 (81.4) | 0.390 |
| LCX | 52 (52.5) | 34 (54.8) | 29 (67.4) | 0.247 |
| RCA | 48 (48.5) | 35 (56.5) | 28 (65.1) | 0.174 |
| NYHA functional class III–IV | 20 (20.2) | 23 (37.1) | 18 (47.9)# | 0.012* |
| IVS, mm | 10 ± 1 | 10 ± 1 | 11 ± 1 | 0.065 |
| LVPW, mm | 10 ± 3 | 10 ± 1 | 10 ± 1 | 0.933 |
| LVEDD, mm | 45 ± 6 | 45 ± 5 | 46 ± 4 | 0.385 |
| LVEDV, mL | 88 ± 22 | 86 ± 22 | 95 ± 27 | 0.154 |
| LVESV, mL | 35 ± 11 | 35 ± 10 | 41 ± 13#& | 0.008* |
| LVMI, g/m2 | 87.6 (75.6, 100.0) | 89.9 (77.0, 109.7) | 95.9 (79.2, 118.1) | 0.060 |
| E/A | 0.8 (0.7, 0.9) | 0.8 (0.6, 1.0) | 0.7 (0.6, 0.9)# | 0.040* |
Data are presented as mean ± SD or median (interquartile range) for continuous variables, and count (%) for categorical variables
LAD: left anterior descending artery; LCX: left circumflex artery; RCA: right coronary artery; NYHA: New York Heart Association; IVS: interventricular septum; LVPW: left posterior ventricular wall; LVEDD: left ventricular end-diastolic diameter; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; LVMI: left ventricular mass index; E/A: mitral inflow peak early velocity/mitral inflow peak late velocity; E/e′: mitral inflow peak early velocity/mitral annular peak early velocity; LVEF: left ventricular ejection fraction; GLS: global longitudinal strain
#p < 0.05 versus no walls group. &p < 0.05 versus 1–2 walls group
Receiver operating characteristic curve analysis of multiple parameters to predict adverse events
| AUC | 95% CI | Cutoff value | Sensitivity | Specificity | ||||
|---|---|---|---|---|---|---|---|---|
| LVEF, % | 0.55 | 0.48–0.62 | 0.334 | 0.040* | 0.003* | 60 | 70.0 | 46.6 |
| E/A | 0.54 | 0.47–0.61 | 0.440 | 0.027* | 0.002* | 0.8 | 56.7 | 55.2 |
| E/e′ | 0.53 | 0.46–0.60 | 0.648 | 0.049* | 0.002* | 12.2 | 50.0 | 75.9 |
| GLS, -% | 0.70 | 0.63–0.76 | < 0.001* | / | 0.249 | 15.4 | 56.7 | 77.0 |
| PSI, % | 0.76 | 0.70–0.82 | < 0.001* | 0.249 | / | 10.4 | 63.3 | 81.0 |
AUC: area under the curve; CI: confidence interval; LVEF: left ventricular ejection fraction; E/A: mitral inflow peak early velocity/mitral inflow peak late velocity; E/e′: mitral inflow peak early velocity/mitral annular peak early velocity; GLS: global longitudinal strain; PSI: post-systolic index
*p < 0.05
Fig. 2Event-free survival. Kaplan–Meier survival curves for adverse events prediction by (A) LVEF; (B) E/A; (C) E/e′; (D) GLS; (E) PSI; (F) the number of left ventricle walls with PSS. LVEF: left ventricular ejection fraction; E/A: mitral inflow peak early velocity/mitral inflow peak late velocity; E/e′: mitral inflow peak early velocity/mitral annular peak early velocity; GLS: global longitudinal strain; PSI: post-systolic index; PSS: post-systolic shortening
Cox regression analysis of multiple variables on the composite endpoint
| Univariable analysis | Multivariable analysis | |||||
|---|---|---|---|---|---|---|
| HR (95% CI) | Model 1 | Model 2 | ||||
| Male | 1.06 (0.46–2.40) | 0.898 | ||||
| Age | 1.06 (1.01–1.10) | 0.008* | 1.03 (0.99–1.07) | 0.137 | 1.03 (0.99–1.07) | 0.102 |
| Body mass index, kg/m2 | 1.00 (0.87–1.14) | 0.952 | ||||
| Heart rate, bpm | 0.99 (0.95–1.03) | 0.602 | ||||
| Systolic blood pressure, mmHg | 1.02 (1.00–1.04) | 0.060 | ||||
| Diastolic blood pressure, mmHg | 1.03 (1.00–1.06) | 0.081 | ||||
| Revascularization therapy | 1.42 (0.59–3.41) | 0.429 | ||||
| Hypertension | 2.38 (1.01–5.59) | 0.046* | 2.12 (0.86–5.25) | 0.102 | 1.71 (0.69–4.28) | 0.250 |
| Diabetes | 1.65 (0.78–3.45) | 0.187 | ||||
| Carotid plaque | 1.22 (0.55–2.68) | 0.625 | ||||
| Number of coronary stenoses | 1.18 (0.84–1.66) | 0.336 | ||||
| NYHA functional class III–IV | 2.24 (1.05–4.76) | 0.036* | 1.45 (0.66–3.18) | 0.350 | 1.29 (0.59–2.80) | 0.523 |
| LVEF, % | 0.94 (0.88–1.01) | 0.104 | 0.97 (0.90–1.05) | 0.422 | 0.97 (0.90–1.05) | 0.508 |
| E/A | 0.22 (0.04–1.22) | 0.082 | ||||
| E/e′ | 0.97 (0.87–1.07) | 0.560 | ||||
| GLS, -% | 0.85 (0.76–0.95) | 0.004* | 0.95 (0.84–1.08) | 0.419 | 0.96 (0.85–1.09) | 0.965 |
| PSI, % | 1.19 (1.09–1.29) | 0.001* | 1.15 (1.04–1.27) | 0.005* | ||
| Per 1 increase in number of walls with PSS | 1.69 (1.39–2.05) | < 0.000* | 1.52 (1.21–1.91) | < 0.000* | ||
HR: hazard ratio; CI: confidence interval; NYHA: New York Heart Association; LVEF: left ventricular ejection fraction; E/A: mitral inflow peak early velocity/mitral inflow peak late velocity; E/e′: mitral inflow peak early velocity/mitral annular peak early velocity; GLS: global longitudinal strain; PSI: post-systolic index; PSS: post-systolic shortening
*p < 0.05
Fig. 3Restricted cubic splines of nonlinear association between LnPSI and hazard ratio. The bold red lines indicate the pooled restricted cubic spline model, and the red filled area indicates the 95% confidence intervals of the pooled curve. PSI: post-systolic index
Fig. 4Event-free survival. Kaplan–Meier survival curves for adverse events prediction in patients with stratification of GLS > 15.4% by (A) GLS; (B) the number of left ventricle walls with PSS. GLS: global longitudinal strain; PSI: post-systolic index; PSS: post-systolic shortening